Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor’s potential

Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor’s potential

  • March 2, 2026

Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema.

Leave A Comment

Fields (*) Mark are Required